Access cutting-edge acute myeloid leukemia treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.
Access acute myeloid leukemia specialists in Baltimore at no cost
This study follows strict safety protocols and ethical guidelines
All study-related acute myeloid leukemia treatment provided free
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Sponsor: Daiichi Sankyo
Check if you qualify for this acute myeloid leukemia clinical trial in Baltimore, MD
If you're searching for acute myeloid leukemia treatment options in Baltimore, MD, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.